I langtidsundersøgelsen (006) afbrød 1% af patienterne i hver af behandlingsarmene behandlingen pga. problemer fra lever eller galdeveje.
In the long-term study (006), 1% of patients in each treatment arm discontinued because of liver or biliary system disorders.